The Protease Activated Receptor 1 Gene Variation IVSn-14 A > T is Associated with Distant Metastasis and Cancer Specific Survival in Renal Cell Carcinoma

被引:13
作者
de Martino, Michela
Haitel, Andrea [1 ,2 ]
Schatzl, Georg
Klatte, Tobias [1 ]
机构
[1] Med Univ Vienna, Dept Urol, A-1090 Vienna, Austria
[2] Med Univ Vienna, Dept Clin Pathol, A-1090 Vienna, Austria
关键词
kidney; carcinoma; renal cell; receptor; PAR-1; neoplasm metastasis; polymorphism; single nucleotide; POLYMORPHISM; ADENOCARCINOMA; RISK; POPULATION; EXPRESSION; PROGNOSIS; PREDICTS; MODEL; VEGF;
D O I
10.1016/j.juro.2013.03.041
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: PAR-1 mediates angiogenesis and impacts the process of tumor growth and disease progression. We evaluated the associations of the gene variations PAR-1 IVSn -14 A>T (rs168753), -506 Ins/Del (rs11267092) and -1426 C>T (rs32934) with renal cell carcinoma pathology and cancer specific survival. Materials and Methods: DNA was extracted from the peripheral blood leukocytes of 236 consecutive patients with renal cell carcinoma. Genotyping was done using restriction fragment length polymorphism analysis of polymerase chain reaction amplicons and sequencing. Results: The IVSn -14 AA genotype was associated with a 3.13-fold increased risk of distant metastases (p = 0.015). In addition, cancer specific survival of patients with IVSn -14 AA was significantly worse than in those with AT/TT (HR 2.98, p = 0.019). The 1 and 4-year cancer specific survival rate for AA vs AT/TT was 89% vs 99% and 82% vs 92%, respectively. After adjusting for the stage, size, grade and necrosis (SSIGN) score on multivariable analysis, IVSn -14 AA was identified as an independent adverse prognostic factor (HR 2.72, p = 0.044). The variations -506 Ins/Del and -1426 C>T were not significantly associated with pathological factors or cancer specific survival. Conclusions: Results suggest that the AA genotype of the PAR-1 variation IVSn -14 A>T is associated with an increased risk of metastasis and poorer prognosis of renal cell carcinoma. Therefore, assessing the individual risk based on genotypes may be a helpful adjunct to identify subgroups at high risk for a poor clinical outcome.
引用
收藏
页码:1392 / 1397
页数:6
相关论文
共 30 条
[1]   Protective effect of a thrombin receptor (protease-activated receptor 1) gene polymorphism toward venous thromboembolism [J].
Arnaud, E ;
Nicaud, V ;
Poirier, O ;
Rendu, F ;
Alhenc-Gelas, M ;
Fiessinger, JN ;
Emmerich, J ;
Aiach, M .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (02) :585-592
[2]   CONTROLLING THE FALSE DISCOVERY RATE - A PRACTICAL AND POWERFUL APPROACH TO MULTIPLE TESTING [J].
BENJAMINI, Y ;
HOCHBERG, Y .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1995, 57 (01) :289-300
[3]  
Castaño-Rodríguez N, 2012, ANTICANCER RES, V32, P3715
[4]  
Chang SS, 2010, AJCC CANC STAGING MA, P445
[5]   The CASP8-652 6N Insertion/Deletion Promoter Polymorphism is Associated with Renal Cell Carcinoma Risk and Metastasis [J].
de Martino, Michela ;
Haitel, Andrea ;
Schatzl, Georg ;
Klingler, Hans Christoph ;
Klatte, Tobias .
JOURNAL OF UROLOGY, 2013, 190 (02) :717-722
[6]   Renal Cell Carcinoma Fuhrman Grade and Histological Subtype Correlate With Complete Polymorphic Deletion of Glutathione S-Transferase M1 Gene [J].
De Martino, Michela ;
Klatte, Tobias ;
Schatzl, Georg ;
Remzi, Mesut ;
Waldert, Matthias ;
Haitel, Andrea ;
Stancik, Igor ;
Kramer, Gero ;
Marberger, Michael .
JOURNAL OF UROLOGY, 2010, 183 (03) :878-883
[7]   Prognosis in human melanoma: PAR-1 expression is superior to other coagulation components and VEGF [J].
Depasquale, I. ;
Thompson, W. D. .
HISTOPATHOLOGY, 2008, 52 (04) :500-509
[8]   Proteinase-activated receptors:: novel mechanisms of signaling by serine proteases [J].
Déry, O ;
Corvera, CU ;
Steinhoff, M ;
Bunnett, NW .
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 1998, 274 (06) :C1429-C1452
[9]   An intronic polyrnorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN [J].
Dupont, A ;
Fontana, P ;
Bachelot-Loza, C ;
Reny, JL ;
Bièche, I ;
Desvard, F ;
Aiach, M ;
Gaussem, P .
BLOOD, 2003, 101 (05) :1833-1840
[10]  
Eble J N., 2004, World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs, P9